Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Scientists develop cross-species coronavirus test

In an advance that will help scientists track coronavirus variants in wild and domesticated animals, researchers report they can now detect exposure to the SARS-CoV-2 virus in any animal species.

6 Jul 2023

Advances in influenza research

This interview with Dr. Mohammad S Safiarian, Associate Product Manager at Sino Biological, discusses the advances in influenza research and how effective vaccines are developed.

From Sino Biological Inc. 30 Jun 2023

Understanding the biological effects of SARS-CoV-2 persistence in children

Researchers analyzed the most recent knowledge about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Jun 2023

New study offers clues on how to future-proof covid-19 vaccines

New research examining how frequently our bodies produce broadly neutralizing antibodies (bnAbs) capable of thwarting a range of SARS-CoV-2 variants offers clues on the strategy tweaks that could potentially future-proof COVID-19 vaccines.

26 Jun 2023

Viral clearance: A potential predictor of COVID-19 treatment efficacy

Researchers determine the virological effects of COVID-19 treatment and its clinical efficacy in the same trial.

22 Jun 2023

Treatment with dupilumab leads to sustained improvements in COPD patients with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine.

20 Jun 2023

Battle against RSV: Computational design paves way for new polyvalent vaccine

Research focuses on the design of a multi-epitope polyvalent vaccine against Human Respiratory Syncytial Virus (RSV), a leading cause of lower respiratory tract infections. The study utilizes computational methods and immunoinformatics tools to predict potential vaccine candidates and their interactions with Toll-like receptors (TLRs).

19 Jun 2023

Broader search needed for successful management of eosinophilic gastritis

The good news: a monoclonal antibody treatment called benralizumab proved quite effective in a clinical trial at depleting the number of eosinophils found in the blood and digestive tract tissues of patients with eosinophilic gastritis.

16 Jun 2023

PREACH-M trial: Lenzilumab may improve treatment response in chronic myelomonocytic leukemia

Humanigen, Inc.today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS-pathway mutations.

9 Jun 2023

Study shows how blood makes the brain’s immune cells toxic

In patients with neurological diseases like Alzheimer's disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment.

8 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

MFAP5, a microfibril-associated protein, unveiled as key player in scar formation and wound healing

MFAP5, a microfibril-associated protein, plays a significant role in wound healing by regulating fibroblast function, collagen deposition, and angiogenesis, suggesting its potential as a modulator of scar formation.

1 Jun 2023

Mental health profoundly impacts inflammatory responses in the body

Study uncovered mechanisms by which psychological stress affects bowel inflammation.

30 May 2023

"Smart" sutures can detect inflammation and release drugs

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

16 May 2023

Targeting the hemoglobin problem in sickle cell disease using a new drug

A class of drugs used for their ability to stop tumor cells from dividing is now under study for their potential to reduce the pain and damage caused by sickle cell disease, investigators report.

11 May 2023

UCF researcher develops a new, more precise treatment for acute respiratory viral infections

A University of Central Florida College of Medicine researcher has developed a new, more precise treatment for a major cause of illness around the world each year -; acute respiratory viral infections.

9 May 2023

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Researchers highlighted the pace of development of COVID-19 therapies during the pandemic and the challenges that hinder the widespread availability of anticoronavirals.

8 May 2023

Urgent call for improved diagnostics, treatments, and vaccines against deadly Hantavirus

Scientists discuss hantavirus infections, which are a type of viral hemorrhagic fever that can be transmitted to humans through exposure to infected rodents in endemic areas.

30 Apr 2023

Research identifies Th1 memory CD4+ T cells as key to protect against emerging poxvirus skin infections

Researchers demonstrate that T helper 1 effector memory cluster of differentiation 4 T cells provide immunity against poxviruses

27 Apr 2023

Bioengineered drug candidate can counter S. aureus infection in early tests

Researchers at NYU Grossman School of Medicine and Janssen Biotech, Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus – a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

24 Apr 2023